Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

NCT01156753 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01156753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01156753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
November 30, 2012
Enrollment
120 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer